Invitae will take part in a massive restructuring that will see it lay off more than 1,000 employees, exit some of its under-performing businesses, and reduce the more than 100 countries it serves to ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Overseen by a newly appointed CEO, genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae CEO Ken Knight takes the ...

Invitae Corp (NYSE: NVTA) plans to focus its resources on higher-margin and higher-growth businesses, including oncology, women's health, rare disease, and pharmacogenomics. It will also continue to ...

Invitae is among the companies pioneering genomics. The company is building a platform that can use DNA to drive smarter healthcare decision-making throughout various life stages. However, the company ...

A bankruptcy judge agreed to allow genetics testing company Invitae to start polling creditors on a reorganization plan after altering it to give all unsecured creditors a vote. Judge Michael Kaplan ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...